Discontinued Product

(S)-α-Methyl-3-carboxyphenylalanine (Cat. No. 0857) has been withdrawn from sale for commercial reasons.
Description: Group III mGlu antagonist
Literature (4)

Biological Activity for (S)-α-Methyl-3-carboxyphenylalanine

Potent, highly selective antagonist of L-AP4- induced depression of forskolin-stimulated cAMP production in rat brain cerebrocortical slices; 100 fold less potent versus L-CCG-I -induced depression.

Technical Data for (S)-α-Methyl-3-carboxyphenylalanine

M. Wt 223.23
Storage Store at RT

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for (S)-α-Methyl-3-carboxyphenylalanine

Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service

References for (S)-α-Methyl-3-carboxyphenylalanine

References are publications that support the biological activity of the product.

Bruno et al (1996) Activation of group III metabotropic glutamate receptors is neuroprotective in cortical cultures. Eur.J.Pharmacol. 310 61 PMID: 8880068

Sekiyama et al (1996) Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes. Br.J.Pharmacol. 117 1493 PMID: 8730745

Watkins and Collingridge (1994) Phenylglycine derivatives as antagonists of metabotropic glutamate receptors. TiPS 15 333 PMID: 7992387

Kemp et al (1994) Antagonist effects of 3-carboxy derivatives of phenylglycine and phenylalanine mGluR ligands on cortical adenylyl cyclase activity. Br.J.Pharmacol. 113 147P

Keywords: (S)-a-Methyl-3-carboxyphenylalanine, (S)-a-Methyl-3-carboxyphenylalanine supplier, Glutamate, (Metabotropic), Group, III, Receptors, 0857, Tocris Bioscience

Citations for (S)-α-Methyl-3-carboxyphenylalanine

Citations are publications that use Tocris products.

Currently there are no citations for (S)-α-Methyl-3-carboxyphenylalanine.

Reviews for (S)-α-Methyl-3-carboxyphenylalanine

There are currently no reviews for this product. Be the first to review (S)-α-Methyl-3-carboxyphenylalanine and earn rewards!

Have you used (S)-α-Methyl-3-carboxyphenylalanine?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Learning & Memory Poster

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.